Current recommendations and emerging options for the treatment of allergic rhinitis

References

• Björkstén B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008;19(2):110-24
   PubMed Web of Science ®Google Scholar
• Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. Vital Health Stat 2010;249:1-207
   Google Scholar
• Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013;68:1102-16
   PubMed Web of Science ®Google Scholar
• Greiner AN, Hellings PW, Rotiroti G, et al. Allergic rhinitis. Lancet 2011;378(9809):2112-22
   PubMed Web of Science ®Google Scholar
• Rondòn C, Canto G, Blanca M. Local allergic rhinitis: a new entity, characterization and further studies. Curr Opin Allergy Clin Immunol 2010;10(1):1-7
   PubMed Web of Science ®Google Scholar
• Smurthwaite L, Durham SR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002;2(3):231-8
   PubMedGoogle Scholar
• Powe DG, Jagger C, Kleinjan A, et al. ‘Entopy’: localized mucosal allergic disease in the absence of systemic responses for atopy. Clin Exp Allergy 2003;33(10):1374-9
   PubMedGoogle Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011;106(2 Suppl):S12-16
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol 2013;160(4):393-400
   PubMed Web of Science ®Google Scholar
• Gentile D, Bartholow A, Valovirta E, et al. Current and future directions in pediatric allergic rhinitis. J Allergy Clin Immunol Pract 2013;1:214-26
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Caimmi D, Miraglia Del Giudice M, et al. Recent developments in United airways disease. Allergy Asthma Immunol Res 2012;4(4):171-7
   PubMed Web of Science ®Google Scholar
• Marseglia GL, Merli P, Caimmi D, et al. Nasal disease and asthma. Int J Immunopathol Pharmacol 2011;24(4 Suppl):7-12
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Capasso M, Leonardi S, et al. Impaired FEF25-75 values may predict bronchial reversibility in allergic children with rhinitis or asthma. J Biol Regul Homeost Agents 2012;26(1 Suppl):S19-25
   PubMedGoogle Scholar
• Ciprandi G, Cirillo I, Klersy C, et al. Role of FEF25-75 as an early marker of bronchial impairment in patients with seasonal allergic rhinitis. Am J Rhinol 2006;20:641-7
   PubMedGoogle Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128:1139-50
   PubMed Web of Science ®Google Scholar
• Grubbe RE, Lumry WR, Anolik R. Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2009;19:117-24
   PubMed Web of Science ®Google Scholar
• Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs 2009;69:2541-76
   PubMed Web of Science ®Google Scholar
• Howarth PH. Assessment of antihistamine efficacy and potency. Clin Exp Allergy 1999;29:87-97
   PubMedGoogle Scholar
• Potter P, Maspero JF, Vermeulen J, et al. Rupatadine oral solution in children with persistent allergic rhinitis: a randomized, doubleblind, placebo-controlled study. Pediatr Allergy Immunol 2013;24:144-50
   PubMed Web of Science ®Google Scholar
• Alevizos M, Karagkouni A, Vasiadi M, et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol 2013;111(6):542-7
   PubMed Web of Science ®Google Scholar
• Muñoz-Cano R, Valero A, Izquierdo I, et al. Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design. Allergy Asthma Clin Immunol 2013;9(1):43
   PubMedGoogle Scholar
• Bousquet J, Ansótegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012;28(1):131-9
   PubMed Web of Science ®Google Scholar
• Wolthers OD. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria. Biomed Res Int 2013;2013:626837
   PubMed Web of Science ®Google Scholar
• Ellis AK, Zhu Y, Steacy LM, et al. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol 2013;9(1):16
   PubMed Web of Science ®Google Scholar
• Nielsen LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs 2001;61(11):1563-79
   PubMedGoogle Scholar
• Mygind N, Nielsen LP, Hoffmann HJ, et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 2001;108(Suppl 1):S16-25
   Google Scholar
• Corren J. Intranasal corticosteroids for allergic rhinitis. How do different agents compare? J Allergy Clin Immunol 1999((4 Pt 1):S144-9
   Google Scholar
• Wolthers OD. Impact of inhaled and intranasal corticosteroids on the growth of children. Bio Drugs 2000;13(5):347-57
   Google Scholar
• Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract 2014;2(2):179-85
   PubMed Web of Science ®Google Scholar
• Carr W, Bernstein J, Lieberman P. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129(5):1282-9
   PubMed Web of Science ®Google Scholar
• Zitt M, Kosoglu T, Hubbel J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30(4):317-26
   PubMed Web of Science ®Google Scholar
• Kumar R, Kumar D, Parakh A. Fluticasone furoate: a new intranasal corticosteroid. J Postgrad Med 2012;58(1):79-83
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008;63(10):1292-300
   PubMed Web of Science ®Google Scholar
• Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004;27(12):883-98
   PubMed Web of Science ®Google Scholar
• Allen DB. Systemic effects on intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000;106(Suppl 4):S179-90
   Google Scholar
• Boner AL. Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. J Allergy Clin Immunol 2001;108(Suppl 1):S32-9
   Google Scholar
• Petty DA, Blaiss MS. Intranasal corticosteroids topical characteristics: side effects, formulation, and volume. Am J Rhinol Allergy 2013;27(6):510-13
   PubMedGoogle Scholar
• Mehuys E, Gevaert P, Brusselle G, et al. Self-medication in persistent rhinitis: overuse of decongestants in half of the patients. J Allergy Clin Immunol Pract 2014;2(3):313-19
   PubMedGoogle Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012(23): 3 p preceding table of contents 1-298
   Google Scholar
• Li H, Sha Q, Zuo K, et al. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. J Otorhinolaryngol Relat Spec 2009;71:50-5
   PubMedGoogle Scholar
• Nguyen SA, Psaltis AJ. SchlosserRJ. Isotonic saline nasal irrigation is an effective adjunctive therapy to intranasal corticosteroid spray in allergic rhinitis. Am J Rhinol Allergy 2014. [Epub ahead of print]
   Google Scholar
• Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8
   PubMed Web of Science ®Google Scholar
• Van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76
   PubMed Web of Science ®Google Scholar
• Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 2006;17:49-54
   PubMed Web of Science ®Google Scholar
• Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:551-7
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Altintas D, Rondon C, et al. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol 2013;77(12):1922-4
   PubMedGoogle Scholar
• Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy 2009;64(1):85-95
   PubMed Web of Science ®Google Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: american Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288-96
   PubMed Web of Science ®Google Scholar
• Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract 2014;2(2):144-9
   PubMed Web of Science ®Google Scholar
• Chelladurai Y, Suarez-Cuervo C, Erekosima N, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract 2013;1(4):361-9
   PubMed Web of Science ®Google Scholar
• La Rosa M, Lionetti E, Leonardi S, et al. Specific immunotherapy in children: the evidence. Int J Immunopathol Pharmacol 2011;24(4 Suppl):69-78
   PubMedGoogle Scholar
• Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy 2012;67(9):1087-105
   PubMedGoogle Scholar
• Casale TB, Stokes JR. Immunotherapy: what lies beyond. J Allergy Clin Immunol 2014;133(3):612-19
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA, Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012;129:409-12
   PubMed Web of Science ®Google Scholar
• Barchuk WT, Salapatek AM, Ge T, et al. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol 2013;132(4):838-46.e1-6
   PubMedGoogle Scholar
• Yonekura S, Okamoto Y, Yamamoto H, et al. Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis. Int Arch Allergy Immunol 2013;162(1):71-8
   PubMedGoogle Scholar
• Meltzer EO, Jacobs R, La Force C, et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc 2012;33:249-57
   PubMed Web of Science ®Google Scholar
• Ratner P, Jacobs R, Mohar D, et al. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 mg once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2010;105:471-9
   PubMed Web of Science ®Google Scholar
• Gross GN, Settipane RA, Ford LB, et al. Patient satisfaction with beclomethasone dipropionate nasal aerosol device with integrated dose counter during daily use. Allergy Asthma Proc 2013;34(6):527-33
   PubMed Web of Science ®Google Scholar
• Neffen H, Wingertzahn MA. Ciclesonide, a hypotonic intranasal corticosteroid. Allergy Asthma Proc 2010;31:S29-37
   Google Scholar
• Mohar D, Berger WE, Laforce C, et al. Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. Allergy Asthma Proc 2012;33:19-26
   PubMed Web of Science ®Google Scholar
• Jacobs RL. Ciclesonide for the treatment of seasonal allergic rhinitis. Expert Rev Clin Immunol 2011;7:735-41
   PubMed Web of Science ®Google Scholar
• Berger WE, Mohar DE, LaForce C, et al. A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. Am J Rhinol Allergy 2012;26:302-7
   PubMed Web of Science ®Google Scholar
• Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol 2014; pii S0091-6749(14):00358-3
   Google Scholar
• Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 2013;13(6):933-45
   PubMed Web of Science ®Google Scholar
• Braido F, Sclifò F, Ferrando M, et al. New therapies for allergic rhinitis. Curr Allergy Asthma Rep 2014;14(4):422
   PubMed Web of Science ®Google Scholar
• Babu KS, Polosa R, Morjaria JB. Anti-IgE-emerging opportunities for Omalizumab. Expert Opin Biol Ther 2013;13(5):765-77
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Tseretopoulou X, Priftis K, et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract 2014;2(3):332-40.e1
   PubMed Web of Science ®Google Scholar
• Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014;164(1):46-63
   PubMed Web of Science ®Google Scholar
• Tan Y, Li Y, Liu D, et al. Suplatast tosilate ameliorates airway hyperreactivity and inflammation through inhibition of the GATA-3/IL-5 signaling pathway in asthmatic rats. Mol Med Rep 2013;8(1):161-7
   PubMedGoogle Scholar
• Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther 2013;51(7):576-84
   PubMed Web of Science ®Google Scholar
• Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2014;133(2):414-19
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy 2012;67:1572-9
   PubMed Web of Science ®Google Scholar
• Rimmer J, Peake HL, Santos CM, et al. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2007;37(1):8-14
   PubMed Web of Science ®Google Scholar
• Braido F, Sclifò F, Ferrando M, et al. New therapies for allergic rhinitis. Curr Allergy Asthma Rep 2014;14:422
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang W, Shang J, et al. Immunomodulatory effects of IL-23 and IL-17 in a mouse model of allergic rhinitis. Clin Exp Allergy 2013;43(8):956-66
   PubMedGoogle Scholar
• Grüber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Expert Rev Clin Immunol 2012;8:17-19
   PubMed Web of Science ®Google Scholar
• Guarner F, Bourdet-Sicard R, Brandtzaeg P, et al. Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract Gastroenterol Hepatol 2006;3(5):275-84
   PubMedGoogle Scholar
• Singh M, Ranjan Das R. Probiotics for allergic respiratory diseases—putting it into perspective. Pediatr Allergy Immunol 2010;21:e368-76
   Web of Science ®Google Scholar
• Vliagoftis H, Kouranos VD, Betsi GI, et al. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol 2008;101:570-9
   PubMed Web of Science ®Google Scholar
• Perrin Y, Nutten S, Audran R, et al. Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis. Clin Transl Allergy 2014;4(1):1
   PubMedGoogle Scholar
• Ivory K, Wilson AM, Sankaran P, et al. Oral delivery of a probiotic induced changes at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a randomised clinical trial. PLoS One 2013;8(11):e78650
   Google Scholar
• Costa DJ, Marteau P, Amouyal M, et al. Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study). Eur J Clin Nutr 2014;68:602-7
   PubMed Web of Science ®Google Scholar
• Das RR, Naik SS, Singh M. Probiotics as additives on therapy in allergic airways disease: a systematic review of benefits and risks. Biomed Res Int 2013;2013:231979
   PubMedGoogle Scholar
• Böhm M, Avgitidou G, El Hassan E, et al. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol 2012;269:495-502
   PubMed Web of Science ®Google Scholar
• Cuppari C, Salpietro A, Grasso L, et al. HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment. The Child 2012;1(2):8
   Google Scholar